In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Effectiveness of cardiac rehabilitation in patients with type 2 diabetes mellitus after percutaneous coronary intervention.
Authors : M J Romero Reyes (Seville,ES), N Cobo Gomez (Seville,ES), P Escane Duarte (Seville,ES), R Picon Heras (Seville,ES), R Guerola Segura (Seville,ES), FJ Molano Casimiro (Seville,ES), L Pastor Torres (Seville,ES)
Introduction: Patients with diabetes mellitus are at increased risk of recurrent cardiovascular events after percutaneous coronary intervention.
Purpose: The aim of this study was to asses if cardiac rehabilitation decreases mortality and recurrence of cardiovascular events in this subgroup of patients after percutaneous coronary intervention.
Methods: We performed a retrospective cohort study of 318 consecutive patients with type 2 diabetes mellitus who underwent percutaneous coronary intervention in our hospital between September 2004 and January 2011. We classified the patients in two cohorts according to their participation (n=154) or not (n=164) in a cardiac rehabilitation programme. Events occurring in the first 2 years of follow-up were recorded.
Results: CR was associated with a significant decrease in all-cause mortality (OR 0,105 [95% CI: 0,31–0,356]; p<0,001) and cardiac mortality (OR 0,107 [95% IC: 0,24–0,468]; p<0,001) over a two year follow-up. No significant differences were observed in nonfatal myocardial infarction, stent restenosis and nonfatal stroke.
Conclusion: Participation in a CR programme after percutaneous coronary intervention is associated with a significant reduction in cardiac mortality and all-cause mortality rates in type 2 diabetic patients.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease